Prot#ARGX-113-2003: A Phase 3b, Randomized, Open-label, Parallel-Group Study to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis

Project: Research project

Project Details

StatusActive
Effective start/end date12/17/2112/17/24

Funding

  • INC Research, LLC (Prot#ARGX-113-2003 // Prot#ARGX-113-2003)
  • arGEN-X BV (Prot#ARGX-113-2003 // Prot#ARGX-113-2003)